NCT00277667View on ClinicalTrials.gov

Study of Quetiapine Monotherapy in Ambulatory Bipolar Spectrum Disorder With Moderate-to-Severe Hypomanic Symptoms or Mild Manic Symptoms

PHASE3CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Bipolar Disorder
Interventions
DRUG

Quetiapine

Oral dosing: 50mg (Day 1), 100mg (Day 2), 150mg (Day 3), 200mg (Day 4), followed by flexible dosing from 50mg to 800mg through day 56.

Trial Locations (1)

45267-0559

University of Cincinnati Medical Center, Cincinnati

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

University of Cincinnati

OTHER

lead

Lindner Center of HOPE

OTHER

NCT00277667 - Study of Quetiapine Monotherapy in Ambulatory Bipolar Spectrum Disorder With Moderate-to-Severe Hypomanic Symptoms or Mild Manic Symptoms | Biotech Hunter | Biotech Hunter